tallózása szerző szerint "Grusch, Michael"

A találatok rendezése: Rendezés: Találatok:

  • Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy 
    Cserepes, Mihály; Ostoros, Gyula; Lohinai, Zoltán; Rásó, Erzsébet; Barbai, Tamás; Tímár, József; Rózsás, Anita; Moldvay, Judit; Kovalszky, Ilona; Fábián, Katalin; Gyulai, Márton; Ghanim, Bahil; László, Viktória; Thomas, Klikovits; Hoda, Mir Alireza; Grusch, Michael; Berger, Walter; Klepetko, Walter; Hegedűs, Balázs; Döme, Balázs (2014)
    Background: Platinum-based chemotherapy is the most common treatment in advanced-stage lung adenocarcinoma. Because the clinical significance of KRAS mutational status in this setting has not yet been clearly determined, ...
  • The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition 
    Hager, Sonja; Korbula, Katharina; Bielec, Björn; Grusch, Michael; Pirker, Christine; Schosserer, Markus; Liendl, Lisa; Lang, Magdalena; Grillari, Johannes; Nowikovsky, Karin; Pape, Veronika; Mohr, Thomas; Szakács, Gergely; Keppler, Bernhard K.; Berger, Walter; Kowol, Christian R.; Heffeter, Petra (2018)
    Due to their high biological activity, thiosemicarbazones have been developed for treatment of diverse diseases, including cancer, resulting in multiple clinical trials especially of the lead compound Triapine. During the ...